Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: The Canadian experience

Investigational New Drugs

Volumn 16, Issue 3, 1998, Pages 265-270

  Latreille, J ^a,i   Gelmon, K A ^b   Hirsh, V ^c   Laberge, F ^d   Maksymiuk, A W ^e   Shepherd, F A ^f   Delorme, F ^g   Berille J ^h  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e Saskatoon Cancer Center   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g Rhône Poulenc Rorer ^*  (Canada)

^h SANOFI   (France)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Docetaxel; Non small cell lung cancer; Phase II study

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOCETAXEL; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CANADA; CARCINOMA, NON-SMALL-CELL LUNG; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PREMEDICATION; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0032431890     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006126505910     Document Type: Article

References (23)

1. Ginsberg RJ, Vokes EE, Raben A: Non-small cell lung cancer. In: de Vita Jr FT, Hellman S, Rosenberg SA (eds) Principles and Practice of Oncology. 5th edition. Lippincott-Raven, Philadelphia, 1997, pp 858-911.
2. Feigal EG, Christian M, Cheson B, Grever M, Friedman MA: New chemotherapeutic agents in non-small cell lung cancer. Semin Oncol 20(2): 185-201, 1993
3. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995
4. Feld R, Ginsberg RJ, Payne DG, Shepherd FA: Lung. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds) Clinical Oncology. Churchill Livingstone, New York/Edinbourg/London/Melbourne/Tokyo, 1995, pp 1083-1152
5. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991
6. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, Huber M, Perez-Soler R, Hong WK, Raber M: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12: 1238-1244, 1994
7. Fossella F, Lee JS, Bérille J, Hong WK: Summary of phase II data of docetaxel (Taxotere®), an active agent in the first and second line treatment of advanced non-small cell lung cancer. Semin Oncol 22(Suppl)4: 22-29, 1995
8. Francis PA, Rigas JR, Kris MG, Pisters KNW, Orazem JP, Woolley KJ, Heelan RT: Phase II trial of docetaxel in patients with stage II and IV non-small cell lung cancer. J Clin Oncol 12: 1232-1237, 1994
9. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75: 968-972, 1995
10. Fleming T: One sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151, 1989
11. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14: 65-74, 1987
12. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16-20, 1992
13. Edelman MJ, Gandara DR: Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 37: 385-393, 1996
14. Kris M, Cohen E, Gralla R: An analysis of 134 phase II trials in non-small cell lung cancer (Abstr). IV World Conference on Lung Cancer, Toronto, 1985, p 39
15. Rigas JR: Single-agent docetaxel in previously untreated non-small cell lung cancer. Oncology 11: 17-21, 1997
16. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328: 1323-1332, 1990
17. Van Oosterom AT, Dieras V, Tubiana-Hulin M, Kalla S, Coombes RC, Alakl M, Murawsky M: Taxotere® in previously treated patients with metastatic breast carcinoma: stratification for anthracycline resistance (Abstr 231). Proc Am Soc Clin Oncol 15: 141, 1996
18. van Zandwijk N, Giaccone G: Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol 8: 120-125, 1996
19. Albain KS, Crowley J, Leblanc M, Livingston R: Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626, 1991
20. Bonomi P, Kim K, Chang A, Johnson D: Phase III trial comparing etoposide cisplatin versus taxol with cisplatin-granulocyte-colony stimulating factor versus taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group trial (Abst 1145). Proc Am Soc Clin Oncol 15: 382, 1996
21. Giaccone G, Splinter T, Postmus P, Diaz Fuente M, Van Zandwijk N, de Bruyne C, Sahmoud T: Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non-small cell lung cancer (Abstr 1109). Proc Am Soc Clin Oncol 15: 373, 1996
22. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994
23. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GRE, Laufman LR, Baker LH, Fisher RI, Bearman SI, Taylor SA, Livingston RB: Randomized phase III trial of cisplatin versus cisplatin plus navelbine in treatment of advanced non-small cell lung cancer: report of a South West Oncology Group study (Abst 1110). Proc Am Soc Clin Oncol 15: 374, 1996